Mitotic catastrophe and cancer drug resistance: A link that must to be broken

详细信息    查看全文

• 作者：Tatiana V. Denisenko^a ; ¹ ; Irina V. Sorokina^a ; ¹ ; Vladimir Gogvadze^a ; ^b ; Boris Zhivotovsky^a ; ^b ; ^{Boris.Zhivotovsky@ki.se" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Mitotic catastrophe ; Genomic instability ; Cancer ; Drug resistance
• 刊名：Drug Resistance Updates
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：24
• 期：Complete
• 页码：1-12
• 全文大小：1518 K

文摘

An increased tendency of genomic alterations during the life cycle of cells leads to genomic instability, which is a major driving force for tumorigenesis. A considerable fraction of tumor cells are tetraploid or aneuploid, which renders them intrinsically susceptible to mitotic aberrations, and hence, are particularly sensitive to the induction of mitotic catastrophe. Resistance to cell death is also closely linked to genomic instability, as it enables malignant cells to expand even in a stressful environment. Currently it is known that cells can die via multiple mechanisms. Mitotic catastrophe represents a step preceding apoptosis or necrosis, depending on the expression and/or proper function of several proteins. Mitotic catastrophe was proposed to be an onco-suppressive mechanism and the evasion of mitotic catastrophe constitutes one of the gateways to cancer development. Thus, stimulation of mitotic catastrophe appears to be a promising strategy in cancer treatment. Indeed, several chemotherapeutic drugs are currently used at concentrations that induce apoptosis irrespective of the cell cycle phase, yet are very efficient at triggering mitotic catastrophe at lower doses, significantly limiting side effects. In the present review we summarize current data concerning the role of mitotic catastrophe in cancer drug resistance and discuss novel strategies to break this link.